Stockholm, Sweden – 13 February 2026
Avia Pharma today announces the entering of a strategic partnership and distribution agreement with Pohl-Boskamp, a Germany-based pharmaceutical company, for the Nordic markets. Under the agreement, Avia Pharma will act as Pohl-Boskamp’s official distributor in the Nordic region for the following products and countries:
GeloRevoice® – unique throat lozenges that are specially developed for frequent speakers and singers. Thanks to the special hydrogel complex, typical voice problems such as throat irritation, tickling of the throat and hoarseness are quickly and lastingly relieved. (Denmark, Norway and Sweden)
Nitrolingual® – a sublingual nitroglycerin spray for the treatment of angina pectoris. (Denmark, Norway and Sweden)
Gepan® instill – a bladder instillation containing chondroitin sulphate for the treatment of chronic forms of cystitis, e. g. interstitial cystitis, overactive bladder, chronic recurrent urinary tract inflammation and radiation cystitis. (Denmark, Finland, Norway and Sweden)
The partnership represents an important step in Avia Pharma’s strategy to expand its Nordic portfolio with high-quality specialty products that address clear patient needs.
“We are delighted to enter into this collaboration” says Marie Wikman, Head of Nordics at Avia Pharma. “Pohl-Boskamp’s strong product portfolio and long-standing expertise complement Avia Pharma’s Nordic portfolio and commercial capabilities. We look forward to continuing developing these products in the Nordic market, making them more widely available to healthcare professionals and patients throughout the region”.
“We are looking forward to working with Avia Pharma’s experienced team. Our new partnership is an important step toward raising the awareness of our high-quality-products in the Nordic markets and helping patients recover quickly – in line with our motto: Feel how it works.” says Bodo Heibrock, Senior Director International Sales & Business Development at Pohl Boskamp.
For further information, please contact:
Jacob Calmvik, CEO
Email: Jacob.calmvik@aviapharma.se